The FDA has restored GHK-Cu for non-injectable use to Category 1 of its 503A bulk drug substances list, reversing an April 22, 2026 removal that compounding pharmacies had been scrambling to interpret for the better part of a month
doi: 10.3389/fmed.2024.1449037 Received 24 June 2024 Accepted 23 September 2024 Published 07 October 2024 Volume 11 - 2024 Edited by Yue Liu, Boston Childrens Hospital, Harvard Medical School, United States Reviewed by Kaige Chen, Wake Forest University, United States Yi-Kai Hong, Northwestern University, United States Updates Copyright 2024 Xie, Cao, Shu, Liu and Zhang
Ideal for: Licensed researchers studying tissue repair, wound healing, and regenerative pathways University laboratories investigating copper peptide biology, collagen synthesis, and ECM dynamics Research institutions examining anti-inflammatory, antioxidant, or neuroprotective mechanisms Formulation scientists developing and evaluating topical delivery systems (serum, cream, lotion, toner) for preclinical review If your research requires an active, well-characterized ghk cu copper peptide with an extensive evidence base, this product is designed to match your laboratory needs
These solutions should always be stored at temperatures between 2-8C to ensure their effectiveness and prevent degradation over time
Wang et al., 2024
& Harris, C
